日本脳炎ワクチンの世界市場

◆英語タイトル:MarketVIEW: Japanese encephalitis vaccines
◆商品コード:VACZ712001
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2017年1月
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF、Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Executive Presentation (PDF)USD5,735 ⇒換算¥636,585見積依頼/購入/質問フォーム
PDF+ExcelUSD8,915 ⇒換算¥989,565見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Japanese encephalitis (JE) is an enzootic mosquito-borne viral disease where humans are incidental “dead end” hosts. JE currently affects countries of SE Asia and Western Pacific where around 3 billion people are considered at risk. The disease mainly affects children (< 15yrs) in poor rural areas where it can result in 25% mortality (est 10,000 deaths/yr) or residual neuropsychiatric sequelae (30% of cases). There are no specific treatments for JE.
Vaccines for JE have been available for decades and used in large scale routine immunization programs in South Korea, China and Japan. Older mouse brain derived vaccines are gradually being replaced by live-attenuated (SA 14-14-2, CIBP) and new vero cell derived inactivated vaccines from both local and Western manufacturers. Countries currently not operating JE vaccination programs are predicted to do so in the next 5 years so increasing demand.

This MarketVIEW product is comprised of a comprehensive MS Excel-based model + Summary executive presentation which forecast the potential commercial value of Japanese Encephalitis vaccine(s) across endemic and travel markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments, including catch-up (public sector) down to vaccine type. An up to date review of disease background and epidemiology is included with a review of the competitive environment and forecast GAVI introduction to 2020 and beyond.

THIS PRODUCT IS A SUMMARY PRESENTATION + ONE MODEL

【レポートの目次】

Contents – summary presentation
Contents
Authors note
Executive summary
Contents
Author’s note
Executive Summary
Commercial model: key outputs
JE vaccines: global endemic value by country to 2030 ($m)
JE vaccines: global endemic value by vaccine to 2030 ($m)
JE vaccines: global endemic value by age group to 2030 ($m)
JE vaccines: global endemic volume by country to 2030 (doses)
JE vaccines: global endemic volume by age to 2030 (doses)
JE vaccines: global travel value by origin country to 2030 ($m)
JE vaccines: global travel value by vaccine to 2030 ($m)
Commercial model assumptions
Major model inputs (endemic)
Major model inputs (endemic): country variables
Major model inputs (endemic): vaccines used
Major model inputs (travel) (3 slides)
Major model inputs (military)
Disease background
The virus
Geographic range
Transmission: overview
Transmission: enzootic cycle
Transmission: vector density in Asia
Clinical features of JE infection
Clinical features: comparative burden of mosquito borne disease
JE: treatment and prevention
JE: epidemiology
Epidemiology: WHO reported cases
Epidemiology: risk
JE: Burden/DALYS

Vaccines currently used
Licensed JEV vaccines: brief overview
Chengdu CDIPB: SA14-14-2
Valneva: IXIARO/JESPECT
IXIARO: expected sales revenues by market, 2016
IXIARO: historical sales, 2010-2016
IXIARO: travel market business outlook (2 slides)
IXIARO: revenue forecast to 2026 ($m)
Sanofi Pasteur: IMOJEV
Other JE vaccines
Competitive landscape
JEBIK V: sales 2012-2016 (f)
Kaketsuken: Encevac – suspension
Competitive landscape: WHO prequalification
JE vaccines: country immunization schedules
Country immunization schedules (cont..)
GAVI funding
GAVI introduction to 2020 and beyond
JE vaccine: pricing (endemic)
Pricing (travel/military)
Pricing: comparative analysis
About VacZine Analytics
Disclaimer
Back page
62 slides available in .pdf form

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 日本脳炎ワクチンの世界市場(MarketVIEW: Japanese encephalitis vaccines)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆